Entry |
|
Name |
Enfortumab vedotin (USAN); Enfortumab vedotin (genetical recombination) (JAN); Enfortumab vedotin-ejfv; Padcev (TN) |
Product |
|
Formula |
C6642H10284N1742O2063S46
|
Exact mass |
148930.0517
|
Mol weight |
149022.148
|
Remark |
|
Efficacy |
Antineoplastic, Nectin-4 antibody, Tubulin polymerization inhibitor |
Disease |
|
Comment |
Antibody-drug conjugate
Treatment of cancers expressing Nectin-4
|
Target |
|
Pathway |
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC36 Enfortumab vedotin
D11525 Enfortumab vedotin (USAN) <US>
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
Other
PVRL4 (NECTIN4)
D11525 Enfortumab vedotin (USAN) <US>
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D11525 Enfortumab vedotin (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11525
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11525
|
Other DBs |
|
LinkDB |
|